Stage 2: Silent
出自KMU Wiki
(修訂版本間差異)
| 在2018年3月13日 (二) 17:31所做的修訂版本 (編輯) Guhjy (對話 | 貢獻) ←上一個 |
當前修訂版本 (2018年3月13日 (二) 17:33) (編輯) (撤銷) Guhjy (對話 | 貢獻) |
||
| (2個中途的修訂版本沒有顯示。) | |||
| 第1行： | 第1行： | ||
| 2-3rd year | 2-3rd year | ||
| 40% progress to stage 3 | 40% progress to stage 3 | ||
| - | Pathology | + | *Pathology |
| - | *Thick GBM | + | **Thick GBM |
| **Heparan sulfate lost | **Heparan sulfate lost | ||
| ***Loss of charge selectivity for proteins | ***Loss of charge selectivity for proteins | ||
| ****Proteinuria or albuminuria | ****Proteinuria or albuminuria | ||
| - | *Mesangial expansion or sclerosis | + | **Mesangial expansion or sclerosis |
| - | + | *Pathogenesis | |
| - | *Glomerular hypertension | + | **Glomerular hypertension |
| - | *Proteinuria | + | **Proteinuria |
| - | *Advanced glycosylation end products ↑ | + | **Advanced glycosylation end products ↑ |
| - | *Growth hormone ↑ | + | **Growth hormone ↑ |
| - | *IGF-I ↑ | + | **IGF-I ↑ |
| - | *Angiotensin II ↑ | + | **Angiotensin II ↑ |
| - | *Connective tissues growth factor ↑ | + | **Connective tissues growth factor ↑ |
| - | *Transforming growth factor-β | + | **Transforming growth factor-β |
| - | *Hyperlipidemia | + | **Hyperlipidemia |
當前修訂版本
2-3rd year 40% progress to stage 3
- Pathology
- Thick GBM
- Heparan sulfate lost
- Loss of charge selectivity for proteins
- Proteinuria or albuminuria
- Loss of charge selectivity for proteins
- Mesangial expansion or sclerosis
- Pathogenesis
- Glomerular hypertension
- Proteinuria
- Advanced glycosylation end products ↑
- Growth hormone ↑
- IGF-I ↑
- Angiotensin II ↑
- Connective tissues growth factor ↑
- Transforming growth factor-β
- Hyperlipidemia
